Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

April US FDA Approval Decisions To Cover Cardiomyopathy, CNS And China-Developed Cancer Drugs

Executive Summary

Five novel agents have user fee goal dates in the coming month, the Pink Sheet’s US FDA Performance Tracker shows.

You may also be interested in...



Could The US FDA Set Clinical Trial Diversity Minimums?

Oncology Center of Excellence Director Richard Pazdur asked whether the FDA should have more conversations with sponsors about site selection and percentages of US participants.

Keeping Track: Vijoice, Igalmi Approvals Show New Faces Of Older Drugs; Facility Change Extends Vutrisiran Goal

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Lilly To Decide Next Steps After Formal FDA 'Nay' For First Chinese PD-1

The official verdict is in for sintilimab and the results are not surprising. But some view the setback for "Made In China" innovation as a chance to reflect and move forward.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel